Posted by Michael Wonder on 10 Oct 2017
Agenda for 11 October TC meeting
9 October 2017 - HAS has posted the agenda for the next scheduled TC meeting.
The Transparency Commission will consider the reimbursement of:
- Nivolumab (Opdivo)
- Trabectedin (Yondelis)
- Inotuzumab ozogamicin (Besponsa)
- Cysteamine hydrochloride (Cystadrops)
